BioSpace News Archive

On behalf of the Honourable Patty Hajdu, Federal Minister of Health, Member of Parliament Chris Bittle will announce federal support to help prevent gender-based and family violence.

Regenexx, the world’s largest, cohesive physician group dedicated to practicing advanced orthobiologics and the first to use stem cells in the treatment of many orthopedic injuries, is celebrating its 15th year since inception.

Inteliquet, a leading provider of intelligent technology, advanced insights, and expertise for clinical research, patient treatment and translational medicine, announced findings of a survey aimed at examining adoption of real-world data in healthcare and clinical research.

Cybin, Canada’s premier medicinal mushroom life sciences company with a core focus on advancing psilocybin research and intellectual property is pleased to announce a strategic partnership with the Toronto Centre for Psychedelic Science.

Caris Life Sciences®, today announced the publication of new data in Nucleic Acids Research, illustrating that use of the Company’s proprietary ADAPT Biotargeting System™ can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate (LNCaP).

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Company received CE Mark approval for an expanded indication to treat pediatric patients above 10kg (approximately 22 lbs) with the Senhance® System.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies.

Feb. 12, 2020 12:00 UTC Viralym-M pivotal and proof-of-concept studies to be initiated in 2020 for treatment and prevention of severe and life-threatening viral diseases CAMBRIDGE, Mass.--( BUSINESS WIRE )-- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to Viralym-M (ALVR105), the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell the

Feb. 12, 2020 12:00 UTC Pear Therapeutics to Participate in 9 th Annual SVB Leerink Global Healthcare Conference BOSTON--( BUSINESS WIRE )-- Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will participate in the 9 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26 at the Lotte New York Palace. About Pear Thera

CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including both the MIDAS XII, a next-generation GMP compliant supercritical CO2 extraction technology, as well as industrially scaled CO2 facility solutions.